Loading…
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-17M | $-14M | $-12M | -10.0% | - | -12.0% |
| 2024 | $0M | $-16M | $-16M | $-6M | -28.3% | - | 85.5% |
| 2023 | $0M | $-9M | $-8M | $-8M | -150.4% | - | -20.1% |
| 2022 | $0M | $-11M | $-11M | $-7M | -104.2% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 0 | 0 | 0 | 0 |
| Operating Revenue | - | 0 | 0 | 0 | 0 |
| Operating Expense | - | 10.54 | 8.83 | 16.16 | 16.70 |
| Research And Development | - | 7.59 | 5.60 | 13.01 | 9.90 |
| Selling General And Administration | - | 2.95 | 3.23 | 3.16 | 6.80 |
| Total Expenses | - | 10.54 | 8.83 | 16.16 | 16.70 |
| Operating Income | - | -10.54 | -8.83 | -16.16 | -16.70 |
| Total Operating Income As Reported | - | -10.54 | -8.83 | -16.16 | -16.70 |
| EBITDA | - | -10.54 | -8.83 | -16.16 | -16.70 |
| Normalized EBITDA | - | -10.54 | -8.83 | -16.16 | -16.70 |
| EBIT | - | -10.54 | -8.83 | -16.16 | -16.70 |
| Interest Income | - | 0.02 | 0.43 | 0.40 | 2.99 |
| Net Interest Income | - | 0.02 | 0.43 | 0.40 | 2.99 |
| Other Non Operating Income Expenses | - | - | - | 0.17 | - |
| Other Income Expense | - | - | - | 0.17 | - |
| Interest Income Non Operating | - | 0.02 | 0.43 | 0.40 | 2.99 |
| Net Non Operating Interest Income Expense | - | 0.02 | 0.43 | 0.40 | 2.99 |
| Pretax Income | - | -10.52 | -8.40 | -15.59 | -13.72 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -10.52 | -8.40 | -15.59 | -13.72 |
| Net Income From Continuing And Discontinued Operation | - | -10.52 | -8.40 | -15.59 | -13.72 |
| Net Income From Continuing Operation Net Minority Interest | - | -10.52 | -8.40 | -15.59 | -13.72 |
| Net Income | - | -10.52 | -8.40 | -15.59 | -13.72 |
| Net Income Common Stockholders | - | -10.52 | -8.40 | -15.59 | -13.72 |
| Net Income Including Noncontrolling Interests | - | -10.52 | -8.40 | -15.59 | -13.72 |
| Normalized Income | - | -10.52 | -8.40 | -15.59 | -13.72 |
| Diluted NI Availto Com Stockholders | - | -10.52 | -8.40 | -15.59 | -13.72 |
| Basic Average Shares | - | 2.54 | 2.76 | 3.79 | 7.41 |
| Diluted Average Shares | - | 2.54 | 2.76 | 3.79 | 7.41 |
| Total Unusual Items | 0 | - | - | - | - |
| Total Unusual Items Excluding Goodwill | 0 | - | - | - | - |
| Special Income Charges | 0 | - | - | - | - |
| General And Administrative Expense | - | 2.95 | 3.23 | 3.16 | 6.80 |
| Other Gand A | - | 2.95 | 3.23 | 3.16 | 6.80 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Monopar Therapeutics Inc.this co. | MNPR | $399M | -29.11 | 2.90 | -10.0% | -20.21 |
| Orthofix Medical Inc. | OFIX | $418M | -4.53 | 0.93 | -20.5% | 51.78 |
| Cross Country Healthcare, Inc. | CCRN | $409M | -4.31 | 1.27 | -29.4% | -4.69 |
| Upstream Bio, Inc. | UPB | $404M | -2.82 | 1.19 | -42.2% | -1.90 |
| AirSculpt Technologies, Inc. | AIRS |
| - |
| - |
| - |
| - |
| $403M |
| -34.53 |
| 4.59 |
| -13.3% |
| 391.43 |
| Community Health Systems, Inc. | CYH | $393M | 0.77 | -0.28 | -36.5% | 5.53 |
| TruBridge, Inc. | TBRG | $391M | 89.74 | 2.20 | 2.4% | 12.54 |
| OmniAb, Inc. | OABI | $386M | -5.95 | 1.44 | -24.3% | -8.06 |
| Compass Therapeutics, Inc. | CMPX | $384M | -5.77 | 1.95 | -33.8% | -5.08 |
| Peer Median | - | -4.42 | 1.36 | -26.8% | 1.81 | |